olgotrelvir

Olgotrelvir (STI-1558) is a novel oral antiviral drug developed as a dual inhibitor targeting both the SARS-CoV-2 main protease (Mpro), an essential enzyme for viral replication, and human cathepsin L (CTSL), a host protease involved in viral entry into cells[1][3][6]. Olgotrelvir is administered as a prodrug that is converted in plasma to its active form, AC1115[7][8]. This dual mechanism of action—blocking both virus replication and entry—aims to enhance antiviral efficacy and reduce the risk of resistance. Olgotrelvir has demonstrated potent activity against multiple SARS-CoV-2 variants, including those resistant to other antivirals such as Paxlovid. Clinical trials have shown that it significantly accelerates symptom recovery and reduces viral load in nonhospitalized patients with mild-to-moderate COVID-19, with a favorable safety profile[3][4]. The drug was developed by Sorrento Therapeutics/ACEA Therapeutics.

Brand names

Ovydso

Other names

olgotrelvir sodium